Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• High Estrogen Levels May Lead to Recurrence

  Published on March 6, 2008 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Women diagnosed with early-stage breast cancer that came back (recurred) had higher blood estrogen levels than women diagnosed with early-stage breast cancer that didn't come back.

• Postmenopausal Women Benefit from Longer Hormonal Therapy

  Published on December 11, 2007 at 12:00 am

  • Tags: Arimidex, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.

• Chemotherapy and Aromatase Inhibitors Can Cause Bone Loss

  Published on September 19, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  A new study provides more evidence that bone loss is a significant risk for women who receive chemotherapy and/or an aromatase inhibitor to treat breast cancer.

• Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects

  Published on September 6, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.

• Hormonal Therapy Medicines Have Improved Survival

  Published on April 23, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), Aromatase Inhibitors, and Planning Hormonal Therapy

  Hormone-receptor-positive breast cancer survival rates have increased faster than survival rates for hormone-receptor-negative breast cancer.

• Aromatase Inhibitors Offer Better Survival Than Tamoxifen for Postmenopausal Women

  Published on February 12, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.

• Too Many Women Stop Taking Tamoxifen Early

  Published on January 22, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.

• Switching from Tamoxifen to Aromatase Inhibitor Improves Survival

  Published on November 16, 2006 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), Aromatase Inhibitors, and Planning Hormonal Therapy

  Switching to Arimidex after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.

• Femara Reduces Recurrence Risk

  Published on October 2, 2006 at 12:00 am

  • Tags: Femara, Tamoxifen, and After surgery (also called "adjuvant")

  Hormonal therapy has been shown to be very effective in reducing the risk of hormone-receptor-positive, early-stage breast cancer coming back (recurring) in postmenopausal women. To reduce the risk of ...